HIV-1低水平病毒血症可预测瑞士HIV队列研究中接受抗逆转录病毒治疗参与者的病毒学失败
该研究纳入瑞士HIV队列研究中1999年7月至2023年4月启动抗逆转录病毒治疗且治疗6个月后HIV RNA<200拷贝/mL的8132名参与者,采用时间更新Cox比例风险模型分析低水平病毒血症与后续病毒学失败(≥200拷贝/mL)的关联。中位随访4.7年,低水平病毒血症与后续病毒学失败风险升高相关,最高低水平病毒血症类别关联最强(风险比3.3,与不可检测病毒载量比较)。
要点
- 低水平病毒血症与后续病毒学失败风险升高相关,最高类别风险比3.3。
- 该关联在调整人口学和临床特征(包括依从性和治疗方案)后仍存在。
- 检测到低水平病毒血症应促使采取适当措施以降低后续病毒学失败风险。
核心结论
- 低水平病毒血症与后续病毒学失败风险强烈相关,即使在调整人口学和临床特征(包括依从性和治疗方案)后仍存在。
- 检测到低水平病毒血症应促使采取适当措施以降低后续病毒学失败风险。
研究设计与样本
- 研究纳入瑞士HIV队列研究中1999年7月至2023年4月启动抗逆转录病毒治疗且治疗6个月后HIV RNA<200拷贝/mL的参与者,共8132人,总随访49579人年。
- 采用纵向收集数据,应用时间更新Cox比例风险模型分析低水平病毒血症与后续病毒学失败(定义为≥200拷贝/mL)的关联。
- 低水平病毒血症通过HIV RNA值的时间更新曲线下面积(AUC)量化,分为不可检测或基于AUC三分位数的低、中、高类别。
主要发现
- 中位随访时间4.7年,中位HIV RNA测量次数16次。
- 参与者中位年龄38岁,75.9%为男性,74.4%为白人,45.9%为HIV-1 B亚型。
- 低水平病毒血症与后续病毒学失败风险升高相关,最高低水平病毒血症类别在所有纳入变量(包括种族/民族、年龄和抗逆转录病毒治疗)中关联最强(风险比3.3,与不可检测病毒载量比较)。
临床怎么用
- 作者认为,检测到低水平病毒血症应促使采取适当措施以降低后续病毒学失败风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most individuals receiving combination antiretroviral therapy (ART) have human immunodeficiency virus (HIV) plasma viral loads below the limit of detection. However, episodes of low-level viremia (LLV) are observed in subsets of individuals, the risk factors and clinical significance of which remain debated. METHODS: We included participants enrolled in the Swiss HIV Cohort Study, starting ART between July 1999 and April 2023, with HIV RNA values <200 copies/mL 6 months after ART initiation. Using longitudinally collected data, we applied a time-updated Cox proportional hazards model to determine the association of LLV with the risk of subsequent viral failure, defined as ≥200 copies/mL. LLV was quantified by the time-updated area under the curve (AUC) of HIV RNA values, categorized as undetectable or, based on AUC tertiles, low, intermediate, or high. RESULTS: We included 8132 participants with a total of 49 579 person-years of follow-up. The median follow-up time was 4.7 years, and the median number of HIV RNA measurements was 16. Participants had a median age of 38 years, 75.9% were male, 74.4% were white, and 45.9% had HIV-1 subtype B. LLV was associated with an increased risk of subsequent viral failure, with the highest LLV category showing the strongest association (hazard ratio, 3.3 [for comparison with undetectable viral load]) among all included variables, including race/ethnicity, age, and ART. CONCLUSIONS: LLV was strongly associated with risk of subsequent viral failure, even after adjustment for demographic and clinical characteristics, including adherence and treatment regimen. The detection of LLV should prompt appropriate measures to decrease the risk of subsequent viral failure.
引用
- Lanz C, Meier J, Stöckle M, et al. HIV-1 Low-Level Viremia Predicts Viral Failure in Participants on Antiretroviral Therapy in the Swiss HIV Cohort Study. Clin Infect Dis. 2025. PMID: 39570670. doi:10.1093/cid/ciae569
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。